Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile PTEN inact mut
Therapy AZD8186 + Docetaxel
Indication/Tumor Type Advanced Solid Tumor
Response Type no benefit

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
PTEN inact mut Advanced Solid Tumor no benefit AZD8186 + Docetaxel Phase I Actionable In a Phase I trial, treatment with the combination of AZD8186 and Taxotere (docetaxel) was generally well tolerated but demonstrated limited efficacy with an overall response rate of 5.6% (1/18), clinical benefit rate of 22.2% (4/18), and median progression-free survival of 3 months in patients with advanced solid tumors harboring PTEN inactivating mutations (n=21) or PIK3CB activating mutations (n=3) (PMID: 40939237; NCT03218826). 40939237
PubMed Id Reference Title Details
(40939237) A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors. Full reference...